Novinky

2017 Market Review – Biosimilar Medicines Markets

Biosimilar medicines are transforming treatment by enabling better access to biological medicines while improving the sustainability of European healthcare budgets. For the first time, Medicines for Europe has reviewed the policies supporting biosimilar medicines in Europe in the '2017 Market Review – Biosimilar Medicines Markets'. Viac >>

 

Predpis na lieky či výmenný lístok nemajú byť viac povinne papierové

Nové zmeny majú byť v novele zákona o zdravotnej starostlivosti. Viac >>

 

Konferencia Dostupnosť liekov v SR

Komora pre medicínske právo - MEDIUS zorganizovala 20.júna 2017 konferenciu s názvom Dostupnosť liekov v SR: Konflikt princípov venovanú otázkam systému mimoriadnych objednávok liekov. Viac >>

 

Emergentný systém

Systém mimoriadnych objednávok liekov spolu s novou úpravou vývozu kategorizovaných liekov zamestnáva naplno myseľ nejedného lekárnika, výrobcu či distribútora. Viac >>

 

Generic Drug Prices Rise When Market Competition Drops

Generic drug price increases are strongly linked to market competition, according to data published online July 3 in the Annals of Internal Medicine. Viac >>

 

Latest Data Shows the Need to Promote Biosimilar and Value Added Medicines for Better Health

Recognising that biosimilar medicines can vastly improve access to biological medicines, the IGBA has produced a wealth of new material to better inform patients, physicians and governments on the science that underpins these important therapies and benefits that they bring. Viac >>

 

62% of Medicines Dispensed in Europe are Generic, according to IMS New Data

Public health: new IMS data reveals the growing importance of generic medicines for public health as they now account for 62% of medicines dispensed in Europe delivering huge value while impacting only 4% of total healthcare budgets. Viac >>

 

Ingrid Schwarzenberger, new Chair of the IGBA Biosimilars Committee

IGBA is pleased to announce today the nomination of Ingrid Schwarzenberger, Head Global Regulatory Affairs at Sandoz Biopharmaceuticals, as the new Chair of the IGBA Biosimilars Committee Viac >>

 

«zobraziť 1 z 2 strán»